3篇
您的检索式：作者名="Zeneng Cheng"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Determination of 20(S)-protopanaxadiol in human plasma by HPLC–MS/MS:application to a pharmacokinetic study显示文摘A rapid,specific and sensitive HPLC-MS/MS method was developed and validated for the determination of 20(S)-protopanaxadiol(PPD)in human plasma.PPD and the internal standard PD were extracted from plasma by liquid-liquid extraction with cyclohexane-methylene dichloride(2:1,v/v).The separation was performed on a HyPURIYTY C18 column using methanol-5 mM ammonium formate(90:10,v/v)as mobile phase at a flow rate of 0.35 mL/min.Mass spectrometric detection was carried out by electrospray ionization(ESI)in the positive ion mode using multiple reaction monitoring(MRM).The monitored transitions were m/z 425.4-217.2 for PPD and at m/z 461.4-425.5 for PD.The method was linear over the range 0.512-100 ng/mL with a lower limit of quantification(LLOQ)of 0.512 ng/mL.The mean extraction recovery of PPD was greater than 78.2%and no significant matrix effect was detected.The intra-and inter-day precisions were less than 10%and the biases below 4%for PPD.The validated method was applied to a three-level single-dose clinical pharmacokinetics study of 12 healthy Chinese volunteers and the main pharmacokinetic parameters of PPD were obtained. | Feifan Xie Sanwang Li Zeneng Cheng Xingling Liu Hong Zhang Peijiong Li Zhi Liu Xin Guo Peng Yu | 2013 | Acta Pharmaceutica Sinica B2013，3，6： | 3 |
| 2 | Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of agomelatine in Chinese subjects显示文摘The aim of this study was to apply the reference-scaled average bioequivalence(RSABE)approach to evaluate the bioequivalence of 2 formulations of agomelatine,and to investigate the pharmacokinetic properties of agomelatine in Chinese healthy male subjects.This was performed in a single-dose,randomized-sequence,open-label,four-way crossover study with a one-day washout period between doses.Healthy Chinese males were randomly assigned to receive 25 mg of either the test or reference formulation.The formulations were considered bioequivalent if 90% confidence intervals(CIs)for the log-transformed ratios and ratio of geometric means(GMR)of AUC and C_(max) of agomelatine were within the predetermined bioequivalence range based on RSABE method.Results showed that both of the90% CIs for the log-transformed ratios of AUC and C_(max) of 7-desmethyl-agomelatine and 3-hydroxyagomelatine were within the predetermined bioequivalence range.The 90% CIs for natural logtransformed ratios of C_(max) ,AUC_(0–t)and AUC_(0–∞) of agomelatine(104.42–139.86,101.33–123.83 and97.90–117.94)were within the RSABE acceptance limits,and 3-hydroxy-agomelatine(105.55–123.03,101.95–109.10 and 101.72–108.70)and 7-desmethyl-agomelatine(104.50–125.23,102.36–111.50 and101.62–110.64)were within the FDA bioequivalence definition intervals(0.80–1.25 for AUC and0.75–1.33 for C_(max)).The RSABE approach was successful in evaluating the bioequivalence of these two formulations. | Fang Tang Rui Zhou Zeneng Cheng Guoping Yang Aiqiao Chen Zhi Liu Hongyi Tan Shuang Yang Sanwang Li Lingli Mu Peng Yu | 2016 | Acta Pharmaceutica Sinica B2016，6，1： | 2 |
| 3 | Determination of nifeviroc, a novel CCR5 antagonist: Application to a pharmacokinetic study显示文摘 | Wei Wu Dong Xie Zeneng Cheng Zhi Liu Liling Ran Zhenkun Gu Peng Yu | 2011 | Journal of Pharmaceutical and Biomedical Analysis2011，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员